{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:49:52Z","timestamp":1786988992258,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.euf.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T04:27:15Z","timestamp":1634876835000},"page":"1031-1041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"given":"Jeroen","family":"Van Besien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne Xavier","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Pietropaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Merckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"De Coninck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2021.10.002_b0005","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00345-019-03012-1","article-title":"Complications of ureteroscopy: a complete overview","volume":"38","author":"De Coninck","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0010","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/01.ju.0000048980.33855.90","article-title":"Indwelling ureteral stents: evaluation of symptoms, quality of life and utility","volume":"169","author":"Joshi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0015","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0022-5347(17)37976-4","article-title":"Vesicoureteral reflux in patients with double pigtail stents","volume":"146","author":"Mosli","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1089\/end.2006.0252","article-title":"Pilot study of ureteral movement in stented patients: first step in understanding dynamic ureteral anatomy to improve stent comfort","volume":"21","author":"Chew","year":"2007","journal-title":"J Endourol"},{"key":"10.1016\/j.euf.2021.10.002_b0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1089\/end.2007.9949","article-title":"Effects of proximal and distal ends of double-J ureteral stent position on postprocedural symptoms and quality of life: a randomized clinical trial","volume":"21","author":"Al-Kandari","year":"2007","journal-title":"J Endourol"},{"key":"10.1016\/j.euf.2021.10.002_b0030","first-page":"412","article-title":"A ureteral stent crossing the bladder midline leads to worse urinary symptoms","volume":"70","author":"Taguchi","year":"2017","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/JU.0000000000001098","article-title":"Effects of silicone hydrocoated double loop ureteral stent on symptoms and quality of life in patients undergoing flexible ureteroscopy for kidney stone: a randomized multicenter clinical study","volume":"204","author":"Wiseman","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0040","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00345-016-1988-y","article-title":"Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms","volume":"35","author":"Abdelhamid","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0045","first-page":"247","article-title":"Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy","volume":"41","author":"Lee","year":"2013","journal-title":"Urol Res"},{"key":"10.1016\/j.euf.2021.10.002_b0050","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1464-410X.2011.10170.x","article-title":"Meta-analysis showing the beneficial effect of \u03b1-blockers on ureteric stent discomfort","volume":"108","author":"Lamb","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.10.002_b0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12894-015-0050-5","article-title":"The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo","volume":"15","author":"Kwon","year":"2015","journal-title":"BMC Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0060","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/end.2014.0715","article-title":"Effects of \u03b1-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis","volume":"29","author":"Zhou","year":"2015","journal-title":"J Endourol"},{"key":"10.1016\/j.euf.2021.10.002_b0065","article-title":"PRISMA-combined a-blockers and antimuscarinics for ureteral stent-related symptoms: a meta-analysis","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.euf.2021.10.002_b0070","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2015.07.041","article-title":"EAU guidelines on urolithiasis","volume":"69","author":"Tekg\u00fcl","year":"2016","journal-title":"Eur Assoc Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0075","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.juro.2016.05.090","article-title":"Surgical management of stones: American Urological Association\/Endourological Society guideline, part I","volume":"196","author":"Assimos","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0080","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1569-9056(11)60870-1","article-title":"The efficacy and tolerability of mirabegron in patients with overactive bladder\u2014results from a European-Australian phase III trial","volume":"10","author":"Khullar","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euf.2021.10.002_b0085","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/01.ju.0000049198.53424.1d","article-title":"Ureteral stent symptom questionnaire: Development and validation of a multidimensional quality of life measure","volume":"169","author":"Joshi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0090","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association Symptom Index for benign prostatic hyperplasia","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0095","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.urology.2013.04.031","article-title":"A prospective evaluation of pain associated with stone passage, stents, and stent removal using a visual analog scale","volume":"82","author":"Kuehhas","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.euf.2021.10.002_b0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.euf.2021.10.002_b0105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","article-title":"Symptom assessment tool for overactive bladder syndrome\u2014overactive bladder symptom score","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.euf.2021.10.002_b0110","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2021.10.002_b0115","first-page":"76","article-title":"The role of mirabegron in relieving double-J stent-related discomfort: a randomized controlled clinical trial","volume":"74","author":"Galal","year":"2021","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0120","first-page":"54","article-title":"Treatment of ureteral catheter related symptoms; mirabegron versus tamsulosin\/solifenacin combination: a randomized controlled trial","volume":"73","author":"Sahin","year":"2020","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0125","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bju.14416","article-title":"Does mirabegron relieve ureteric stent-related discomfort ? A prospective, randomized, multicentre study","volume":"122","author":"Tae","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.10.002_b0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/luts.12320","article-title":"Does tamsulosin or mirabegron improve ureteral stent-related symptoms ? A prospective placebo-controlled study","volume":"13","author":"Yavuz","year":"2021","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2021.10.002_b0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5455\/jmas.113358","article-title":"Effectiveness of using solifenacin compared to mirabegron after double-J stent installation for treatment of lower urinary tract symptoms (LUTS)","volume":"10","author":"Palinggi","year":"2020","journal-title":"J Med Allied Sci"},{"key":"10.1016\/j.euf.2021.10.002_b0140","first-page":"8","article-title":"Effectiveness of tamsulosin compared with mirabegron in treatment of double-J stent-related lower urinary tract symptoms","volume":"4","author":"Alexander","year":"2020","journal-title":"Int J Med Rev Case Rep"},{"key":"10.1016\/j.euf.2021.10.002_b0145","first-page":"145","article-title":"The efficacy of mirabegron for the relief of ureteral stent-related symptoms","volume":"74","author":"Otsuki","year":"2020","journal-title":"Acta Med Okayama"},{"key":"10.1016\/j.euf.2021.10.002_b0150","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13857","article-title":"Effects of mirabegron on JJ stent-related symptoms: a multicentric study","volume":"75","author":"Cinar","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2021.10.002_b0155","first-page":"68","article-title":"Mirabegron plus tolterodine vs tamsulosin plus tolterodine vs tolterodine monotherapy for stent related symptoms\u2014a prospective randomized study for patient reported outcomes","volume":"26","author":"Joshi","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0160","article-title":"LBA01-03 Comparison of mirabegron, solifenacin and tamsulosin for stent related symptoms","volume":"203","author":"Chandna","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0165","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s11255-017-1667-y","article-title":"Expression of \u03b2-adrenergic receptor subtypes in human normal and dilated ureter","volume":"49","author":"Shen","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euf.2021.10.002_b0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bju.12730","article-title":"Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a \u03b23-adrenoceptor agonist (mirabegron) for overactive bladder (OAB)","volume":"115","author":"Rossanese","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.10.002_b0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.10.002_b0180","article-title":"EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of","author":"Gravas","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.euf.2021.10.002_b0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1756287212457114","article-title":"Mirabegron: a review of recent data and its prospects in the management of overactive bladder","volume":"4","author":"Sacco","year":"2012","journal-title":"Ther Adv Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921002741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921002741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:52:39Z","timestamp":1762498359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456921002741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2405456921002741"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2021.10.002","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}